- Home
- CRDF vs OCFT Comparison
CRDF vs OCFT Comparison
Compare CRDF & OCFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- OCFT
- Stock Information
- Founded
- CRDF 1999
- OCFT 2015
- Country
- CRDF United States
- OCFT China
- Employees
- CRDF N/A
- OCFT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- OCFT Computer Software: Programming Data Processing
- Sector
- CRDF Health Care
- OCFT Technology
- Exchange
- CRDF Nasdaq
- OCFT Nasdaq
- Market Cap
- CRDF 233.5M
- OCFT 236.7M
- IPO Year
- CRDF N/A
- OCFT 2019
- Fundamental
- Price
- CRDF $4.04
- OCFT $7.53
- Analyst Decision
- CRDF Strong Buy
- OCFT
- Analyst Count
- CRDF 6
- OCFT 0
- Target Price
- CRDF $11.92
- OCFT N/A
- AVG Volume (30 Days)
- CRDF 1.4M
- OCFT 48.3K
- Earning Date
- CRDF 08-07-2025
- OCFT 08-15-2025
- Dividend Yield
- CRDF N/A
- OCFT N/A
- EPS Growth
- CRDF N/A
- OCFT N/A
- EPS
- CRDF N/A
- OCFT N/A
- Revenue
- CRDF $587,000.00
- OCFT $260,815,958.00
- Revenue This Year
- CRDF N/A
- OCFT N/A
- Revenue Next Year
- CRDF N/A
- OCFT $6.37
- P/E Ratio
- CRDF N/A
- OCFT N/A
- Revenue Growth
- CRDF N/A
- OCFT N/A
- 52 Week Low
- CRDF $2.01
- OCFT $0.87
- 52 Week High
- CRDF $5.64
- OCFT $7.58
- Technical
- Relative Strength Index (RSI)
- CRDF 65.93
- OCFT 72.16
- Support Level
- CRDF $3.07
- OCFT $7.13
- Resistance Level
- CRDF $4.22
- OCFT $7.55
- Average True Range (ATR)
- CRDF 0.22
- OCFT 0.15
- MACD
- CRDF 0.08
- OCFT 0.02
- Stochastic Oscillator
- CRDF 87.35
- OCFT 91.23
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).